AI Article Synopsis
- Frailty impacts about 50% of patients with heart failure with reduced ejection fraction (HFrEF) and significantly increases the risk of death.
- The relationship between frailty and HFrEF worsens each condition, leading to a cycle of decline in health.
- Despite being at higher risk, frail patients often receive less treatment due to fears of side effects, although evidence shows that heart failure medications are generally safe for them and require a team approach for effective management.
Article Abstract
Frailty affects half of all patients with heart failure with reduced ejection fraction (HFrEF) and carries a ∼2-fold increased risk of mortality. The relationship between frailty and HFrEF is bidirectional, with one condition exacerbating the other. Paradoxical to their higher clinical risk, frail patients with HFrEF are more often under-treated due to concerns over medication-related adverse clinical events. However, current evidence suggests consistent safety of HF medical therapies among older frail patients with HFrEF. A multidisciplinary effort is necessary for the appropriate management of these high-risk patients which focuses on the optimization of known beneficial therapies with a goal-directed effort toward improving quality of life.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.hfc.2024.06.005 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!